-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--May 5, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases,

-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--May 5, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported

-- Management to Host Conference Call at 4:30 p.m. ET Today -- PASADENA, Calif. --(BUSINESS WIRE)--May 8, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases,

Conference call to be held today at 4:30 p.m. EDT

Conference call to be held today at 4:30 p.m. ET

MONROVIA, Calif. , March 7, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the fourth

-- Reported promising preliminary data from Phase 2 study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) ----Announced strategic collaboration with Novartis for bispecific antibodies---- Robust cash position supports operations beyond 2020 ---- Management to host conference call today at 4:30 p.m. ET --

-- Broadening Tumor Microenvironment (TME)-Targeting Bispecific Pipeline with XmAb®24306, Targeting IL-15/ILRa for Multiple Oncology Indications -- -- Expect to Initiate Phase 3 Trial of XmAb®5871 in IgG4-Related Disease (IgG4-RD) in 2H18 -- -- Expect to Announce Initial Data from Phase 2 Trial of

- Initial Data from Phase 1 Study of XmAb®14045 Presented at ASH 2018; Multiple Complete Remissions Achieved in Advanced AML Patient Population; Study on Partial Clinical Hold Pending Resolution with FDA - - Research and License Agreement for XmAb®24306 and IL-15 Cytokines Provides $120 Million

-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--Feb. 24, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported